Login to Your Account

Clinic Roundup

Friday, January 25, 2013
• Curis Inc., of Lexington, Mass., said the first patient has been treated in a Phase I study of CUDC-907 in patients with relapsed or refractory lymphoma or multiple myeloma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription